Clinical Trial

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Study acronym: ALTAIR
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-05-21; most recent amendment 2026-07-20.
Status change: Not Yet Recruiting → Recruiting 2025-12-17
Status change: Recruiting → Not Yet Recruiting 2025-08-22
Status change: Not Yet Recruiting → Recruiting 2025-06-25
Trial Details
NCT Number NCT06996782
Lead Sponsor AstraZeneca
Conditions Advanced or Metastatic Non-small Cell Lung Cancer
Enrollment 152 participants
Start Date 2025-11-24
Primary Completion 2029-02-23 (estimated)
Study Completion 2029-02-23 (estimated)
Updated on ClinicalTrials.gov 2026-07-21